Cat.No. : CSC-RO0448 Host Cell: CT26
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0448 |
| Description | This cell line is derived from CT26 and is engineered to stably overexpress Human ERBB2. |
| Target Gene | ERBB2 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | CT26 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Well-known receptor tyrosine kinase HER2, often referred to as ERBB2, is overexpressed in several types of cancer, including gastric and breast ones. HER2 is a main target for treatments as its overexpression results in tumor development and poor prognosis. Comparatively to the 4T1.2/HER2 cells, the researchers investigated the anticancer efficacy of CT26/HER2 cells expressing human ERBB2. Although the CT26/HER2 model showed increasing tumor development, the 4T1.2/HER2 model showed tumor regression caused by HER2-specific immune responses, mostly CD8+ cytotoxic T lymphocytes (CTLs). Fascinatingly, despite immunological-stimulating substances including CD80 and myeloid-derived suppressor cells, CT26/HER2 tumors were resistant to the generated immune responses.
Figure 1. The researchers challenged BALB/c mice with varying numbers of CT26/HER2 and 4T1.2/HER2 cells to assess tumor growth and regression. (Nilofar Danishmalik S, et al., 2017)
Creative Biogene's Human ERBB2 Stable Cell Line - CT26 may be utilized to study HER2-targeted treatments, immune response regulation, and novel immunotherapies to boost anticancer activity.
A: The ERBB2 gene encodes for the human epidermal growth factor receptor 2, also known as HER2. This protein is a tyrosine kinase receptor involved in cell growth and proliferation. ERBB2 is overexpressed in certain types of cancer, notably breast cancer, where it can drive tumor growth and metastasis. It is a target for therapies such as trastuzumab (Herceptin).
A: ERBB2 contributes to cancer development by promoting uncontrolled cell growth and survival. When overexpressed, it can activate signaling pathways that lead to increased proliferation, invasion, and angiogenesis. ERBB2 can also promote cancer cell migration and metastasis by interacting with other growth factor receptors.
A: Targeting the ERBB2 gene and its protein product is a key strategy in the treatment of certain cancers. Targeted therapies, such as monoclonal antibodies (e.g., Herceptin) and tyrosine kinase inhibitors, can block the function of ERBB2, slowing or stopping the progression of cancer. These treatments are particularly effective in HER2-positive breast cancer.
A: The expression of the ERBB2 gene is regulated by various factors, including growth factors, cytokines, and transcription factors. In normal cells, ERBB2 expression is tightly controlled. However, in cancerous cells, ERBB2 can become overexpressed due to genetic alterations or amplification of the ERBB2 gene, leading to constitutive activation of its signaling pathways and uncontrolled cell growth.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human ERBB2 Stable Cell Line - CT26 maintains high purity, ensuring that researchers can trust the integrity of their results when studying ERBB2-related cancer biology and testing potential therapeutics.
This cell line shows strong adaptability, allowing for robust growth and experimentation in various laboratory conditions, making it a versatile tool for a wide range of research applications.
The Human ERBB2 Stable Cell Line - CT26 exhibits excellent transplantability, enabling researchers to easily establish and maintain the cell line in their own laboratory environments without compromising its stability or performance.
Detailed technical documentation is provided with the Human ERBB2 Stable Cell Line - CT26, equipping researchers with the necessary information to successfully culture, handle, and utilize the cell line for their specific research needs.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
